CN110325211A - 采用抗因子XI/XIa抗体治疗的方法 - Google Patents

采用抗因子XI/XIa抗体治疗的方法 Download PDF

Info

Publication number
CN110325211A
CN110325211A CN201780087088.7A CN201780087088A CN110325211A CN 110325211 A CN110325211 A CN 110325211A CN 201780087088 A CN201780087088 A CN 201780087088A CN 110325211 A CN110325211 A CN 110325211A
Authority
CN
China
Prior art keywords
antibody
seq
fxi
amino acid
fxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087088.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·弗里德曼
Y·赫德尔
M·莱夫科维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202410462229.0A priority Critical patent/CN118320078A/zh
Publication of CN110325211A publication Critical patent/CN110325211A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780087088.7A 2016-12-23 2017-12-22 采用抗因子XI/XIa抗体治疗的方法 Pending CN110325211A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410462229.0A CN118320078A (zh) 2016-12-23 2017-12-22 采用抗因子XI/XIa抗体治疗的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US62/438,654 2016-12-23
US201762589851P 2017-11-22 2017-11-22
US62/589,851 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410462229.0A Division CN118320078A (zh) 2016-12-23 2017-12-22 采用抗因子XI/XIa抗体治疗的方法

Publications (1)

Publication Number Publication Date
CN110325211A true CN110325211A (zh) 2019-10-11

Family

ID=61022382

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780087088.7A Pending CN110325211A (zh) 2016-12-23 2017-12-22 采用抗因子XI/XIa抗体治疗的方法
CN202410462229.0A Pending CN118320078A (zh) 2016-12-23 2017-12-22 采用抗因子XI/XIa抗体治疗的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410462229.0A Pending CN118320078A (zh) 2016-12-23 2017-12-22 采用抗因子XI/XIa抗体治疗的方法

Country Status (9)

Country Link
US (3) US20200231701A1 (https=)
EP (1) EP3558370A2 (https=)
JP (3) JP7110199B2 (https=)
KR (3) KR102702288B1 (https=)
CN (2) CN110325211A (https=)
AU (2) AU2017383537B2 (https=)
CA (1) CA3048157A1 (https=)
IL (2) IL267519B2 (https=)
WO (1) WO2018116267A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003325A (zh) * 2019-12-20 2022-09-02 安托斯治疗股份有限公司 因子xi/xia抗体的药物制剂和剂量方案
CN117487017A (zh) * 2020-07-02 2024-02-02 北京拓界生物医药科技有限公司 抗FXI/FXIa抗体、其抗原结合片段及医药用途
WO2025201156A1 (zh) * 2024-03-28 2025-10-02 施能康生物医药（苏州）有限公司 靶向凝血因子xi的核酸及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru
JP7650807B2 (ja) * 2019-04-16 2025-03-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1213312A (zh) * 1996-01-17 1999-04-07 史密丝克莱恩比彻姆公司 用于治疗血栓形成的抗凝血剂
US20010018052A1 (en) * 1998-08-07 2001-08-30 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
CN1317015A (zh) * 1998-08-28 2001-10-10 基因技术股份有限公司 人抗因子IX/IXa抗体
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
CN1501812A (zh) * 2000-05-15 2004-06-02 ʷ��˿�������ȳ�ķ���޹�˾ 抗血栓剂
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
US20110020349A1 (en) * 2007-11-21 2011-01-27 Andras Gruber Anti-factor xi monoclonal antibodies and methods of use thereof
US20110159006A1 (en) * 2008-06-19 2011-06-30 Erik Hack Use of anti-factor xi antibodies for prevention of thrombus formation
US20110250207A1 (en) * 2008-12-18 2011-10-13 Andras Gruber Anti-fxi antibodies and methods of use
CN104684932A (zh) * 2012-05-10 2015-06-03 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
CN106046154A (zh) * 2011-05-16 2016-10-26 奥姆里克斯生物药品有限公司 血栓形成试剂减少的免疫球蛋白及其制备
CN107922505B (zh) * 2015-06-26 2022-05-06 诺华股份有限公司 凝血因子xi抗体及使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
CN110325211A (zh) 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
CN1213312A (zh) * 1996-01-17 1999-04-07 史密丝克莱恩比彻姆公司 用于治疗血栓形成的抗凝血剂
US20010018052A1 (en) * 1998-08-07 2001-08-30 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
CN1317015A (zh) * 1998-08-28 2001-10-10 基因技术股份有限公司 人抗因子IX/IXa抗体
CN101134107A (zh) * 2000-05-15 2008-03-05 史密丝克莱恩比彻姆公司 抗血栓剂
CN1501812A (zh) * 2000-05-15 2004-06-02 ʷ��˿�������ȳ�ķ���޹�˾ 抗血栓剂
US20110020349A1 (en) * 2007-11-21 2011-01-27 Andras Gruber Anti-factor xi monoclonal antibodies and methods of use thereof
US20110159006A1 (en) * 2008-06-19 2011-06-30 Erik Hack Use of anti-factor xi antibodies for prevention of thrombus formation
US20110250207A1 (en) * 2008-12-18 2011-10-13 Andras Gruber Anti-fxi antibodies and methods of use
CN106046154A (zh) * 2011-05-16 2016-10-26 奥姆里克斯生物药品有限公司 血栓形成试剂减少的免疫球蛋白及其制备
CN104684932A (zh) * 2012-05-10 2015-06-03 拜耳药业股份公司 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
CN107922505B (zh) * 2015-06-26 2022-05-06 诺华股份有限公司 凝血因子xi抗体及使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
周荣富等: "凝血因子与静脉血栓形成", 《国外医学.输血及血液学分册》 *
陈雅慧等: "凝血因子Ⅺ作为抗栓防治新靶点的研究进展", 《中国药理学通报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115003325A (zh) * 2019-12-20 2022-09-02 安托斯治疗股份有限公司 因子xi/xia抗体的药物制剂和剂量方案
CN117487017A (zh) * 2020-07-02 2024-02-02 北京拓界生物医药科技有限公司 抗FXI/FXIa抗体、其抗原结合片段及医药用途
WO2025201156A1 (zh) * 2024-03-28 2025-10-02 施能康生物医药（苏州）有限公司 靶向凝血因子xi的核酸及其用途

Also Published As

Publication number Publication date
CA3048157A1 (en) 2018-06-28
IL267519A (en) 2019-08-29
WO2018116267A3 (en) 2018-08-02
IL316673A (en) 2024-12-01
KR20190099256A (ko) 2019-08-26
KR102702288B1 (ko) 2024-09-05
US20200231701A1 (en) 2020-07-23
KR102918597B1 (ko) 2026-01-28
JP7500662B2 (ja) 2024-06-17
AU2024287181A1 (en) 2025-03-06
IL267519B1 (en) 2024-12-01
JP2020504110A (ja) 2020-02-06
JP7110199B2 (ja) 2022-08-01
US20250197522A1 (en) 2025-06-19
AU2017383537B2 (en) 2024-10-03
EP3558370A2 (en) 2019-10-30
JP2022141831A (ja) 2022-09-29
KR20260023597A (ko) 2026-02-20
IL267519B2 (en) 2025-04-01
US20230002507A1 (en) 2023-01-05
AU2017383537A1 (en) 2019-06-27
JP2024116221A (ja) 2024-08-27
KR20240134248A (ko) 2024-09-06
WO2018116267A2 (en) 2018-06-28
CN118320078A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
JP7823009B2 (ja) 第ｘｉ因子抗体および使用方法
US20250197522A1 (en) Methods of treatment with anti-factor xi/xia antibodies
TW201802121A (zh) 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP2022174193A (ja) 第ｘｉ因子抗体および使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination